Prothena Corporation plc (PRTA) and ZIOPHARM Oncology Inc. (NASDAQ:ZIOP) Comparison side by side

Prothena Corporation plc (NASDAQ:PRTA) and ZIOPHARM Oncology Inc. (NASDAQ:ZIOP) compete against each other in the Biotechnology sector. We will contrast them and contrast their risk, analyst recommendations, institutional ownership, profitability, dividends, earnings and valuation.

Earnings & Valuation

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Prothena Corporation plc N/A 599.54 155.64M -3.94 0.00
ZIOPHARM Oncology Inc. N/A 3996.02 137.25M -0.54 0.00

Table 1 highlights Prothena Corporation plc and ZIOPHARM Oncology Inc.’s top-line revenue, earnings per share (EPS) and valuation.


Table 2 shows us Prothena Corporation plc and ZIOPHARM Oncology Inc.’s return on equity, return on assets and net margins.

Net Margins Return on Equity Return on Assets
Prothena Corporation plc 0.00% -55.2% -38.1%
ZIOPHARM Oncology Inc. 0.00% 58.6% -89.9%

Risk & Volatility

A 2.55 beta indicates that Prothena Corporation plc is 155.00% more volatile compared to Standard & Poor’s 500. ZIOPHARM Oncology Inc. has a 2.57 beta and it is 157.00% more volatile than Standard & Poor’s 500.


Prothena Corporation plc’s Current Ratio is 19.3 while its Quick Ratio is 19.3. On the competitive side is, ZIOPHARM Oncology Inc. which has a 0.8 Current Ratio and a 0.8 Quick Ratio. Prothena Corporation plc is better positioned to pay off short and long-term obligations compared to ZIOPHARM Oncology Inc.

Analyst Recommendations

The following table shown below contains the ratings and recommendations for Prothena Corporation plc and ZIOPHARM Oncology Inc.

Sell Ratings Hold Ratings Buy Ratings Rating Score
Prothena Corporation plc 0 0 0 0.00
ZIOPHARM Oncology Inc. 0 0 2 3.00

Competitively the consensus target price of ZIOPHARM Oncology Inc. is $5.25, which is potential 45.43% upside.

Insider & Institutional Ownership

The shares of both Prothena Corporation plc and ZIOPHARM Oncology Inc. are owned by institutional investors at 0% and 39.8% respectively. About 90.1% of Prothena Corporation plc’s share are held by insiders. Comparatively, 1.7% are ZIOPHARM Oncology Inc.’s share held by insiders.


In this table we show the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Prothena Corporation plc 5.78% 21.45% 19.61% -7.4% -56.84% 38.54%
ZIOPHARM Oncology Inc. -12.58% 20.98% -25.14% -3.9% -25.14% 44.92%

For the past year Prothena Corporation plc was less bullish than ZIOPHARM Oncology Inc.


ZIOPHARM Oncology Inc. beats Prothena Corporation plc on 6 of the 8 factors.

Prothena Corporation plc, a late-stage clinical biotechnology company, focuses on the discovery, development, and commercialization of novel immunotherapies for the treatment of diseases that involve protein misfolding or cell adhesion. It is developing antibody-based product candidates that include NEOD001, a monoclonal antibody that is in Phase III and Phase IIb clinical trials for the treatment of AL amyloidosis; PRX002 that has completed Phase Ib clinical trial for treating Parkinson’s disease and other related synucleinopathies; PRX003, a monoclonal antibody that is in Phase Ib for the treatment of psoriasis and other inflammatory diseases; and PRX004, a monoclonal antibody that is under preclinical development. The company has a license, development, and commercialization agreement with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc. to develop and commercialize antibodies that target alpha-synuclein. Prothena Corporation plc was incorporated in 2012 and is headquartered in Dún Laoghaire, Ireland.

ZIOPHARM Oncology, Inc., a biotechnology company, focuses on acquiring, developing, and commercializing a portfolio of cancer therapies that address unmet medical needs through synthetic immuno-oncology. The company, through its collaboration agreement with Intrexon Corporation, holds certain rights to IntrexonÂ’s synthetic immuno-oncology platform for use in the field of oncology, which includes a clinical stage product candidate, Ad-RTS-IL-12 evaluated for the treatment of metastatic melanoma, unresectable recurrent or metastatic breast cancer, and Grade III malignant glioma (GBM). Its synthetic immuno-oncology platform employs an inducible gene-delivery system that enables controlled in vivo expression of genes that produce therapeutic proteins to treat cancer. The company, under its license agreement with The University of Texas MD Anderson Cancer Center, along with Intrexon hold license to certain technologies relating to novel chimeric antigen receptor (CAR) T cell therapies, non-viral gene transfer systems, genetic modification and/or propagation of immune cells and other cellular therapy approaches, Natural Killer cells, and T cell receptors. It also has a research and development agreement with the National Cancer Institute utilizing Sleeping Beauty System to generate T cells receptors for the treatment of solid tumors. ZIOPHARM Oncology, Inc. is headquartered in Boston, Massachusetts.